Clinical Trials Logo

Clinical Trial Summary

Background: Ramadan Iftar meal typically causes glucose excursions. Dipeptidyl peptidase-4 inhibitors increase serum concentrations of glucagon-like peptide-1 and thus, decrease blood glucose levels with low risk of hypoglycemia. Aim: To investigate the efficacy and safety of vildagliptin as an add-on therapy among adolescents and young adults with type 1 diabetes mellitus (T1DM) on glucose excursions of Iftar Ramadan meals and glycemic metrics during advanced hybrid closed-loop (AHCL) treatment.


Clinical Trial Description

Current management of people with type 1 diabetes mellitus (T1DM) on intensive insulin therapy recognizes carbohydrates as the most important determinant of postprandial glycaemia; hence, worldwide guidelines recommend carbohydrates counting for determining pre-prandial insulin doses. Currently, the insulin to carbohydrate ratio (ICR) is frequently used to calculate the meal insulin dose. However, ICRs are considered difficult, ineffective and inaccurate for some patient, with an estimation error of around 20% in adults demonstrating only modest improvements in glycated hemoglobin (HbA1c). This lack of effectiveness and the wide variability using ICRs suggests it should be improved upon. However, there have been only a few randomized control studies that investigated the efficacy and safety of DPP-4 inhibitors as an add-on drug in patients treated with basal insulin. Therefore, we conducted a one-month randomized control trial to investigate the efficacy and safety of DPP-4 inhibitors as an add-on therapy among adolescents and young adults with T1DM on glucose excursions of Iftar Ramadan meals and glucometrics during AHCL treatment . ;


Study Design


Related Conditions & MeSH terms


NCT number NCT06021119
Study type Interventional
Source Ain Shams University
Contact
Status Completed
Phase Phase 3
Start date March 23, 2023
Completion date April 21, 2023

See also
  Status Clinical Trial Phase
Recruiting NCT04682795 - Comparison of Safety and Efficacy of Needle-Free Injector and Insulin Pen in Patients With T2DM N/A
Recruiting NCT05389839 - Insulin Dose Calculation Software in Insulin Therapy N/A
Completed NCT04711382 - The Use of Faster Acting Aspart in Type 1 Diabetes Patients
Recruiting NCT05947916 - Real Time Continuous Glucose Monitoring System in T2DM With Pregnacy N/A
Recruiting NCT04965051 - Safety and Efficacy of Insulin Degludec/Insulin Aspart in Patients With T1DM N/A